A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 5, 2007, Pages 465-469

  Grosset, D ^a   Taurah, L ^b   Burn, D J ^c   MacMahon, D ^d   Forbes, A ^e   Turner, K ^f   Bowron, A ^g   Walker, R ^g   Findley, L ^f   Foster, O ^h   Patel, K ⁱ   Clough, C ^e   Castleton, B ^j   Smith, S ^h   Carey, G ^j   Murphy, T ^a   Hill, J ^f   Brechany, U ^c   McGee, P ^c   Reading, S ^c   Brand, G ^e   Kelly, L ^k   Breen, K ^k   Ford, S ^k   Baker, M ^l   Williams, A ^m   Hearne, J ^m   Qizilbash, N ^k,n   Ray Chaudhuri, K ^e   more..

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

^b LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f Dagenham Havering PCT Surestart P   (United Kingdom)

^g NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^h ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^j North Surrey Primary Care Trust   (United Kingdom)

^k Parkinson's Disease Society ^*

^l European Parkinson's Disease Association (EPDA)   (United Kingdom)

^m UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁿ Oxon Clinical Epidemiology Services   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE; TRIHEXYPHENIDYL;

AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DETERIORATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; THERAPY DELAY; TREATMENT PLANNING; LONGITUDINAL STUDY; MIDDLE AGED; PATIENT CARE PLANNING; PROGNOSIS;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT CARE PLANNING; PROGNOSIS; QUALITY OF LIFE;

EID: 34247238285     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.098327     Document Type: Article

References (22)

1. Montgomery E, Pan T, Le W, et al. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2004;62:343-5.
2. Chaudhuri KR, Healy D, Schapira AHV. The non motor symptoms of Parkinson's disease. Diagnosis and management. Lancet Neurology 2006;5:235-45.
3. Clarice CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002;360:1767-9.
4. Manas C, Lang AE. Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:143-6.
5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 2001;56(Suppl 5):S1-S886.
6. Jenkinson C, Peto V, Fitzpatrick R, et al. Self-reported functioning and well-being in patients with Parkinson's disease: Comparison of the Short-form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995;24:505-9.
7. Morrish PK. Quality of life in Parkinson's disease. Parkinson Dis 2002;4:1-3.
8. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
9. Jenkinson C, Peto V, Fitzpatrick R, et al. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7.
10. Fukunaga H, Kasai T, Yoshidome H. Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson's disease. Eur Neurol 1997;38(Suppl 2):64-9.
11. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-63.
12. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302.
13. Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease. A 4 year randomised controlled trial. Arch Neurol 2004;61:1044-53.
14. Welsh M, McDermott MP, Holloway RG, et al. Development and testing of the Parkinson's disease quality of life scale. Mov Disord 2003;18:637-45.
15. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-50.
16. Dodel RC, Dubois B, Fahn S, et al. Addressing non-motor impairments in Parkinson's disease: the new version of the UPDRS. Mov Disord. 2005;20: S83(P 227), (Suppl 10).
17. Global Parkinson's Disease Steering Committee. Factors impacting on quality of life in Parkinson's disease; results from an international survey. Mov Disord 2002;17:60-7.
18. Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. An international multicentre pilot study of the first comprehensive self-completed non motor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov Disord 2006;21:916-23.
19. Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. International validation of the first unified non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study. Neurology 2006;66(Suppl 2):S13.001.
20. Schapira AH, Obeso J. Timing of treatment initiationin Parkinson's disease: A need for reappraisal? Ann Neurol 2006;59:559-62.
21. Aminoff MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol 2006;59:562-4.
22. Schrag A, Selia C, Jahanshahi M, et al. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.